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Abstract 
BACKGROUND: Renal stones are the third common disease of the urinary system after infections and diseases 
of the prostate. One of the most common manifestations of this disease after acute pain is nausea and vomiting.  
AIM: To compare the efficacy of metoclopramide and ondansetron in improving nausea and vomiting in patients 
referred to the emergency department with a chief complaint of nausea and vomiting. 
METHODS: This randomised double-blind clinical trial was conducted on patients referred to the emergency 
department of Vali-e Asr Hospital. Mg5 intravenous morphine and ketorolac ampoule were injected to control 
renal colic. Then, patients were randomly divided into two groups. Group 1 consisted of 90 subjects receiving 10 
mg intravenous metoclopramide and group 2 including 90 subjects receiving 4 mg intravenous ondansetron. Vital 
signs were also measured and recorded. 
RESULTS: The mean and standard deviation of nausea in 0, 15, 30, 45, 60 and 120 minutes showed no 
significant difference between the two groups. Mean and standard deviation of vomiting at 0 minutes showed no 
significant difference between the two groups, but the remaining minutes, 15, 30, 45, 60 and 120, exhibited 
significant difference as a comparison of two groups, indicating that vomiting in the metoclopramide group was 
higher than ondansetron group. 
CONCLUSION: Our findings indicated that ondansetron was more effective than metoclopramide in preventing 
and improving vomiting in patients referred to emergency renal colic, where can be used with more efficacy and 
more acceptable side effects to improve nausea and vomiting. 
 
 
 
 
 
 
 
Introduction 
 
Nausea and vomiting are among the most 
common complaints of patients referred to the 
emergency department, and kidney stones are the 
third most commonly reported urinary tract infection 
after infections and prostate diseases [1]. One of the 
most common manifestations of this disease after 
acute pain is nausea and vomiting [2]. 
Currently, Treatments such as venous 
morphine and NSAIDs )Ketorolac( are currently used 
for the treatment of renal colic [3] [4] [5]. Although 
these drugs are widely used in the treatment of renal 
colic, however, these drugs are applied to treat acute 
pain. There is little evidence for the treatment of 
nausea and vomiting in renal colic patients (in 
particular) referred to the emergency department. 
Treatment of nausea and vomiting in patients, in 
addition to facilitating the patient's well-being and 
better collaboration, prevents complications such as 
dehydration, hypokalemia, aspiration [6]. Treatment of 
nausea and vomiting in patients, in addition to 
facilitating the patient's well-being and better 
collaboration, prevents complications such as 
dehydration, hypokalemia, aspiration [7]. Although 
evidence is available on the use of antiemetic drugs in 
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oncology, post-operative nausea and vomiting [8], and 
other conditions associated with nausea and vomiting 
[9], however, little research has been done to apply 
these medications for the treatment of nausea and 
vomiting in patients referred to an emergency such as 
patients with renal colic [6]. Although metoclopramide 
is one of the most widely employed drugs for the 
improvement of nausea and vomiting in patients [6]; 
however, the occurrence of extrapyramidal side 
effects due to the use of this drug has always been a 
factor in the cautious use of the drug [10] [11]. 
Nevertheless, the increasing trend of the use 
of ondansetron in improving nausea and vomiting in 
emergency rooms is seen in comparison with 
metoclopramide [6] [10] [11]. Further evidence has 
focused on the Preventive or therapeutic roles of 
these drugs in patients undergoing chemotherapy and 
surgery [6] [7] [8], where there is little evidence for 
comparing these two drugs in the treatment of 
patients presenting to the emergency department [6]. 
It has recently been reported that the use of serotonin 
receptor antagonist (Granisetron) can be significantly 
more effective than metoclopramide in preventing 
nausea and vomiting in patients undergoing cataract 
surgery [12].  
To prevent postoperative nausea and 
vomiting after laparoscopic cholecystectomy surgery, 
it has been shown that patients receiving ondansetron 
with dexamethasone before surgery had a lower 
prevalence of postoperative nausea and vomiting than 
the dexamethasone group alone [13]. The importance 
of improving nausea and vomiting in patients referred 
to an emergency such as patients with renal colic is 
well known. The prevention of complications from 
continuous nausea and vomiting and the lack of 
evidence for drug therapies in the emergency 
department, such as metoclopramide and serotonin 
receptor antagonists (ondansetron), suggest that 
comparative studies are required about these drugs. 
Therefore, the present study was aimed to 
compare the efficacy of metoclopramide and 
ondansetron in the improvement of nausea and 
vomiting in patients referred to the emergency 
department. 
 
 
Material and Methods 
 
A randomised, double-blind, clinical trial study 
was conducted among patients referring to the 
emergency ward of Vali-e-Asr Hospital in Arak, Iran 
with renal colic and nausea and vomiting. The 
occurrence of renal colic was determined based on 
the medical history of the subjects and the clinical 
manifestations of these patients (type and severity of 
pain and blood in the urine) (3 and 14). The sampling 
method was carried out using available samples 
based on inclusion and exclusion criteria. 
The inclusion criteria were considered as 
follow: 1) patients with renal colic and complained of 
nausea and vomiting; 2) patients classified as ASA I 
and II; 3) patients 18 to 80 years; 4) obtaining 
informed consent from patients. 
The exclusion criteria included: 1) 
hypotension (systolic blood pressure < 90) and 
unstable hemodynamics in general; 2) drug addiction; 
3) uncontrolled underlying disease (Parkinson's 
disease, restless leg syndrome, epilepsy, 
gastrointestinal bleeding, Pheochromocytoma, etc.) 
[2]; 4) recent use of central nervous system 
depressants; 5) recent use of anti-nausea and 
vomiting drugs (at least the past 8 hours); 6) a 
previous known allergic reaction to metoclopramide or 
ondansetron. 
Patients willing to participate in the study were 
evaluated regarding the inclusion and exclusion 
criteria, and basic information (age and sex) was then 
obtained. For all patients, 5 mg intravenous morphine 
was injected with distilled water to a final volume of 10 
cc, and patients received Ketorolac ampules for 
controlling renal colic [4] [5]. Then, the patients were 
randomly divided into 2 groups: group 1 (90 subjects 
receiving 10 mg intravenous metoclopramide) and 
group 2 (90 subjects receiving 4 mg intravenous 
ondansetron). It should be noted that the patients of 
the two groups were matched regarding age and sex. 
Patients were evaluated for the response variables at 
the 0 and 30 minutes after drug injection, that were 
considered as follow: 1) the severity of nausea; 2) the 
number of vomiting; 3) vital signs (systolic, diastolic 
and patient temperature); 4) the need for additional 
drug therapy after 30 minutes to improve nausea and 
vomiting; 5) drug side effects. It is worth noting that 
the patients were matched in two groups according to 
their age, sex and severity of nausea (5-10 cm based 
on VAS).  
The severity of nausea in the two groups was 
evaluated before the injection of drugs (0), and 30 
minutes after taking the drugs by VAS (Visual 
Analogue Scale). This criterion consists of a 10 cm 
ruler extending longitudinally between zero and 10, in 
which the zero number indicates no pain, and the 
number 10 indicates an unbearable pain. Patients 
were asked to mark their pain in this ruler the patient's 
markup distance from point 0 indicates the patient's 
pain level [15]. 
The frequency of vomiting was also evaluated 
from patients 30 minutes before injection and up to 30 
minutes after medication administration based on 
patient information and medical history. The vital signs 
of the patients were measured at 0 and 30 minutes. 
Drug complications were also documented by the 
presence of the following variables or other symptoms 
(based on the diagnosis of an emergency physician) 
after the injection of drugs based on the patient's 
history and doctor's visit. 
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Criteria for metoclopramide included 
akathisia, dyskinesia, and other extrapyramidal side-
effects, dizziness, restlessness, muscle spasm, 
sweating, etc. The ondansetron criteria were as 
follows: dizziness, abdominal pain, rash, diarrhoea, 
etc. It is noteworthy that the task of selecting patients 
and prescribing drugs for patients was to the 
emergency medicine specialist. The resident 
researcher is responsible for reviewing and recording 
the clinical response variables of patients. In this 
study, assistant specialist and patients are blind to the 
type of injectable treatment. For this reason, the drug 
content in the 10 cc syringes was first prepared by a 
nurse and administered by the assistant specialist 
who was blind to the type of treatment. 
 Because in the treatment of patients referred 
to the emergency department the first exposure to 
anaesthetics and vomiting drugs (such as 
metoclopramide or endonestrone) is used, the 
placebo group was not considered to be due to the 
deprivation of these patients. Regarding the treatment 
of patients referred to the emergency department in 
the first step with anti-nausea and vomiting drugs 
(such as metoclopramide or ondansetron), the 
placebo group was not considered in the study due to 
the deprivation of these patients from treatment. 
Data analysis was performed using SPSS 21 
software. To analyse the results, we used mean 
indexes, standard deviation, standard error, the 
percentage of frequency. Moreover, the covariance 
analysis test, Chi-square and Independent T-test or its 
nonparametric equation or its nonparametric equation 
were used to compare the mean. 
 
 
Results 
 
In this double-blind clinical trial, 180 patients 
were enrolled, and 90 patients were randomly 
assigned to receive metoclopramide and 90 patients 
to the ondansetron group. 
The mean and standard deviation in the 
metoclopramide group and ondansetron group 
determined to be 34.56 ± 8.98 and 33.2 ± 8.5, 
respectively. There was no statistically significant 
difference between the two groups regarding age (P = 
23.88). Mean, and standard deviation of 
metoclopramide group was calculated as 171.48 ± 
6.26 while this level was determined to be 172.77 ± 
5.32 for ondansetron group, no statistically significant 
difference was found between the two groups 
regarding height (P = 307). As shown in Table 1, the 
mean and standard deviation of pain score at 0, 30, 
and 60 minutes did not show a significant difference. 
This suggests that the severity of pain in the 
ondansetron group was less than the metoclopramide 
group at these moments. 
Table 1: Mean and standard deviation of pain score in control 
and case groups; T indicates the time 
 Group Mean 
Standard 
Deviation 
P value 
T 0 
Metoclopramide 79.8 88.0 
0.408 
Ondansetron 09.7 98.0 
T 30 
Metoclopramide 79.4 44.1 
0.001 
Ondansetron 18.4 70.0 
T 60 
Metoclopramide 09.8 44.0 
0.001 
Ondansetron 48.2 47.0 
 
The mean and standard deviation of systolic 
blood pressure in 0 minutes were determined in the 
metoclopramide and ondansetron groups as 136.74 ± 
10.15 and 137.03 ± 7.54, respectively, where there 
was no statistically significant difference between the 
two groups for systolic blood pressure (P = 0.829). 
The mean and standard deviation of systolic 
blood pressure of 30 minutes in metoclopramide and 
ondansetron groups were 130.62 ± 7.81 and 128.75 ± 
8.22, respectively. There was no significant difference 
between the two groups regarding systolic blood 
pressure at 30 min (P = 0.120). The mean and 
standard deviation of systolic blood pressure during 
60 minutes in the metoclopramide group were 
determined as 124.91 ± 9.05, while these values for 
the ondansetron group was calculated to be 124.73 ± 
6.24. However, there was no significant difference 
between the two groups regarding systolic blood 
pressure (P = 0.088). 
On the other hand, the mean and standard 
deviation of diastolic blood pressure in 0 minutes was 
determined in metoclopramide and ondansetron 
groups as 81.68 ± 6.61 and 81.33 ± 6.78, 
respectively, which demonstrated no significant 
difference between the two groups regarding diastolic 
blood pressure (p = 722). 
Furthermore, the mean and standard 
deviation of diastolic blood pressure were determined 
in the metoclopramide group during the 30 and 60 
minutes as 77.51 ± 7.63 and 73.58 ± 7.44, 
respectively, while these values in the ondansetron 
group were 76.22 ± 7.10 and 73.33 ± 6.75 were 
calculated. According to the P value, there was no 
significant difference between the two groups 
regarding diastolic blood pressure in the mentioned 
minutes (P = 0.243; p = 0. 810).  
Table 2: Mean and heart rate deviation in case and control 
groups; T shows time 
 Group Mean 
Standard 
Deviation 
P value 
T 0 
Metoclopramide 14.74 41.8 
4840.  
Ondansetron 70.74 47.4 
T 30 
Metoclopramide 44.82 17.4 
0.001 
Ondansetron 88.97 41.8 
T 60 
Metoclopramide 81.99 99.4 
0.001 
Ondansetron 98.98 77.2 
 
The mean and standard deviation of heart 
rate at 0, 30, and 60 minutes after receiving 
metoclopramide and ondansetron by patients are 
summarised in Table 2. The results of this study 
revealed that there was a significant difference in 
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heart rate between the two groups receiving the drug 
30 and 60 minutes after the intervention, indicating 
that the heart rate in the metoclopramide group was 
higher as compared to the ondansetron group (p = 
0.001; p = 0.001). 
Based on the results presented in Table 3, the 
mean and standard deviation of body temperature in 
0, 30 and 60 minutes after intervention were 
calculated in metoclopramide and ondansetron 
groups. There was a statistically significant difference 
between the two groups regarding body temperature 
after 0 and 30 minutes (p = 0.001; p = 0.002). This 
finding suggests that body temperature was lower in 
the metoclopramide group when comparing with the 
ondansetron group in times above. 
Nevertheless, the mean and standard deviation of 
body temperature after 60 minutes in two groups did 
not exhibit significant difference (p = 1.000). 
Table 3: Mean and deviation of morphine in both case and 
control groups 
 Group Mean  
Standard 
Deviation 
P value 
Morphine at 
0 min 
Metoclopramide 74.4 72.0 
0.448 
Ondansetron 71.4 91.0 
Morphine at 
30min 
Metoclopramide 94.0 81.1 
0.484 
Ondansetron 48/0 28/1 
 
The mean and standard deviation of the need 
for morphine at 0 and 30 minutes in both groups were 
shown in Table 4, where no significant difference was 
observed between the two groups at both times. 
Table 4: Mean and standard deviation of morphine in both case 
and control groups; T indicates the time 
 Group Mean 
Standard 
deviation 
P value 
Morphine 
T0 
Metoclopramide 74.4 72.0 
0.653 
Ondansetron 71.4 91.0 
Morphine 
T30 
Metoclopramide 94.0 81.1 
0.484 
Ondansetron 48.0 28.1 
 
As indicated in Table 5, the mean and 
standard deviation of nausea in 0, 15, 30, 45, 60 and 
120 minutes after intervention in the two groups did 
not show a significant difference. 
Table 5: Mean and standard deviation of nausea rate in case 
and control groups; T indicates the time 
Group  Mean 
ا Standard 
deviation 
P value 
Vomiting at 
0 min 
Metoclopramide 02.8 42.0 
1.000 
Ondansetron 08.8 98.0 
Vomiting at 
15 min 
Metoclopramide 41.1 40.0 
0.001 
Ondansetron 84.1 42.0 
Vomiting at 
30 min 
Metoclopramide 44.0 49.0 
0.001 
Ondansetron 84.0 48.0 
Vomiting at 
45 min 
Metoclopramide 88.0 47.0 
0.001 
Ondansetron 04.0 20.0 
Vomiting at 
60 min 
Metoclopramide 12.0 82.0 
0.001 
Ondansetron 08.0 84.0 
Vomiting at 
120 min 
Metoclopramide 09.0 24.0 
0.001 
Ondansetron 02.0 81.0 
 
Furthermore, the results of the present study 
showed that the mean and standard deviation of 
vomiting in both groups were not statistically 
significant at 0 minutes, while after intervention, there 
was a significant difference between the two groups, 
where vomiting in minutes after intervention (Time: 0, 
16, 30, 45, 60, 120) was significantly higher in the 
metoclopramide group than the ondansetron group. 
 
 
Discussion 
 
Renal colic is one of the most common 
urological emergencies that is very painful for the 
patient. The renal colic annually affects 1.2 million 
people, accounting for about 1% of hospital 
admissions [16]. The incidence of kidney stones for 
men and women is about 12% and 4% throughout life, 
respectively, which the disease is affected by age, 
family history, race, place of residence, occupation 
[17]. 
This double-blind clinical trial was conducted 
to compare the efficacy of Metoclopramide and 
ondansetron in the treatment of nausea and vomiting 
in patients with renal colic. The results of our study 
showed that there was no statistically significant 
difference between the two groups regarding age, 
height and weight, where the two groups were 
matched. There was no statistically significant 
difference between the mean score of pain in 0 
minutes in the intervention and control groups. 
However, there was a significant difference between 
the two groups regarding mean pain score in the 30th 
and 60th minutes, which indicates the severity of pain 
in the ondansetron group was less than the 
metoclopramide group. 
Moreover, there was no significant difference 
between systolic and diastolic blood pressure in the 
two groups at 0, 30 and 60 minutes. Furthermore, no 
significant difference was found between the two 
groups in terms of heart rate at 0 minutes; however 
the mean difference was statistically significant 
between the two groups in terms of heart rate at 30 
and 60 minutes, indicating that the heart rate was 
lower in the metoclopramide group at 30 and 60 
minutes as compared to the ondansetron group. 
Based on the data presented here, the mean 
and standard deviation of body temperature at 0 and 
30 minutes exhibited a significant difference between 
the two groups, indicating that the body temperature 
in the metoclopramide group was lower than the 
ondansetron group. The mean and standard deviation 
of initial morphine and morphine levels of 30th 
minutes did not reveal any significant difference 
between the two groups. Also, the mean and standard 
deviation of nausea in minutes 0, 15, 30, 45, 60 and 
120 were not significantly different between the two 
groups. Mean, and standard deviation of vomiting was 
not significantly different between the two groups at 0 
minutes, while the remaining minutes, 15, 30, 45, 60 
and 120, demonstrated a significant difference 
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between the two groups, indicating that the vomiting 
rate in the metoclopramide group was higher when 
comparing with ondansetron group. 
As other previous study indicated the 
decreased rate of nausea severity for nausea and 
vomiting were determined to be similar for 20 mg 
intravenous metoclopramide, and 4 mg intravenous 
ondansetron, as well as placebo. However, this was 
not significant, and the changes were not significant in 
the two drug groups compared to the placebo group 
[6], while, the rate of nausea was similar in both 
groups in our study, but the vomiting rate in the 
ondansetron group was lower than the 
metoclopramide group [6]. 
Zahedi study has shown that both 
metoclopramide and ondansetron have been 
significantly and prominently effective in preventing 
nausea and vomiting in these patients during spinal 
anaesthesia for cesarean section, and their effect on 
reducing nausea and vomiting is significantly greater 
compared with placebo group. While our findings 
revealed that the effect of ondansetron on nausea and 
vomiting was more than metoclopramide, which our 
results were not consistent with the findings of the 
study above [18]. It has been reported that droperidol 
was more effective than metoclopramide or 
prochlorperazine in patients with moderate to severe 
nausea, but extrapyramidal symptoms could be 
increased, where metoclopramide and 
prochlorperazine have had a proportional effect on the 
improvement of nausea and vomiting of patients 
referred to the emergency department, as well as 
we're not seen to be more effective compared to the 
saline placebo [19]. Our study on nausea recovery 
was consistent with the study above. Contrary, the 
results of vomiting improvement were not similar to 
the present study. 
Another study showed that ondansetron and 
metoclopramide, plus dexamethasone, did not show a 
significant effect on postoperative nausea and 
vomiting after laparoscopic cholecystectomy surgery 
and was not consistent with our results [20]. 
The findings of our study revealed that 
ondansetron was more effective than metoclopramide 
in preventing and improving vomiting in patients 
referred to emergency suffering from renal colic. 
Therefore, ondansetron can be used with more 
efficacy and more acceptable side effects to improve 
nausea and vomiting. 
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